Drugs / BBM-F101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06207552 | Feb 2024 → Jun 2025 overdue | Fabry disease | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBM-F101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06207552 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated virus (AAV) gene therapy product” NCT06207552 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT06207552 ↗ |